FOLFOXIRI protocol clinical trials
How each study uses FOLFOXIRI protocol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the FOLFOXIRI protocol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- FOLFOXIRI Protocol
- 5
Studies by the year they started
5 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 5
Catharina Ziekenhuis Eindhoven (1) · Kasr El Aini Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Centre Hospitalier Universitaire Dijon (1) · Al-Azhar University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses FOLFOXIRI protocol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown PrimaryRecruitingPhase 2Centre Hospitalier Universitaire DijonNCT04325425Written as FOLFOXIRI ProtocolHow we know
- Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two StudyRecruitingPhase 2Al-Azhar UniversityNCT06575127Written as FOLFOXIRI ProtocolHow we know
- Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal CancerNot yet recruitingPhase 3Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT03975049Written as FOLFOXIRI ProtocolHow we know
- Induction Chemotherapy for Locally Advanced Rectal CancerActive, not recruitingPhase 2Catharina Ziekenhuis EindhovenNCT04838496Written as FOLFOXIRI ProtocolHow we know
- Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal CarcinomaCompletedPhase 2Kasr El Aini HospitalNCT05316818Written as FOLFOXIRI ProtocolHow we know
Codes
What other systems call FOLFOXIRI protocol · ClinicalTrials.gg INT004905
- MeSH (NLM) C509829FOLFOXIRI protocolOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509829 | FOLFOXIRI protocol | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.